PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32734548-3	2020	Based on clinical trials, FL1-2 is treated with rituximab (R) or obinutuzumab plus bendamustine (B) or CHOP, while FL3B is treated with R-CHOP.	Bendamustine Hydrochloride	83-95	FL1	Homo sapiens	26-31
32860715-0	2021	Extended follow-up of CD4+ T cell recovery kinetics in a large cohort of patients with B-cell lymphoproliferative disease treated with Rituximab-Bendamustine.	Bendamustine Hydrochloride	145-157	CD4 molecule	Homo sapiens	22-25
33440131-6	2021	Additionally, analysis of the relationships between rash related to bendamustine and sex or age showed significant relationships for female sex and age younger than 70 years (ROR=2.247 and 2.176, respectively).	Bendamustine Hydrochloride	68-80	receptor tyrosine kinase like orphan receptor 2	Homo sapiens	175-180
32978820-1	2021	Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown.	Bendamustine Hydrochloride	0-12	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	86-88
32765499-0	2020	Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3.	Bendamustine Hydrochloride	0-12	basic leucine zipper transcription factor, ATF-like 3	Mus musculus	99-104
32835553-1	2020	A recent phase II trial showed that use of polatuzumab vedotin in combination with bendamustine plus rituximab (Pola-BR) in transplant-ineligible patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) resulted in longer progression-free survival and overall survival compared to bendamustine plus rituximab (BR) alone.	Bendamustine Hydrochloride	305-317	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	112-116
32871991-0	2020	Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?	Bendamustine Hydrochloride	30-42	DNA damage inducible transcript 3	Homo sapiens	114-118
30187811-0	2019	Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.	Bendamustine Hydrochloride	0-12	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	127-131
32149078-5	2020	In addition, this bendamustine-derived drug showed both a HDACi effect as demonstrated by histone hyperacetylation and p21 transcription and a DNA-damaging effect as shown by an increase in gamma-H2AX.	Bendamustine Hydrochloride	18-30	H3 histone pseudogene 16	Homo sapiens	119-122
31073022-0	2019	Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.	Bendamustine Hydrochloride	18-30	DNA damage inducible transcript 3	Homo sapiens	147-151
31358733-1	2019	In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m2), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one.	Bendamustine Hydrochloride	31-43	BH3 interacting domain death agonist	Homo sapiens	8-29
30468254-0	2019	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.	Bendamustine Hydrochloride	34-46	Bruton tyrosine kinase	Homo sapiens	10-13
30468254-7	2019	Our results demonstrate that CC-292 is a specific BTK inhibitor with promising performance in combination with bendamustine in CLL.	Bendamustine Hydrochloride	111-123	Bruton tyrosine kinase	Homo sapiens	50-53
32606733-1	2020	Abstract: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL.	Bendamustine Hydrochloride	245-257	CD79b molecule	Homo sapiens	41-46
32231196-6	2020	RESULTS: The high CD5 expression level was linked to better bendamustine (BEN) and cyclophosphamide (CP) CLL B cells response in contrast to B cells with low CD5 expression.	Bendamustine Hydrochloride	60-72	CD5 molecule	Homo sapiens	18-21
32231196-6	2020	RESULTS: The high CD5 expression level was linked to better bendamustine (BEN) and cyclophosphamide (CP) CLL B cells response in contrast to B cells with low CD5 expression.	Bendamustine Hydrochloride	74-77	CD5 molecule	Homo sapiens	18-21
30187811-4	2019	BENDA and BENDA + RIT increased expression of BAX and BBC3 in IGVH-MUT and IGVH-UNMUT groups, and significant differences in expression of above genes after BENDA + RIT were observed between both groups.	Bendamustine Hydrochloride	0-5	BCL2 associated X, apoptosis regulator	Homo sapiens	46-49
30187811-4	2019	BENDA and BENDA + RIT increased expression of BAX and BBC3 in IGVH-MUT and IGVH-UNMUT groups, and significant differences in expression of above genes after BENDA + RIT were observed between both groups.	Bendamustine Hydrochloride	0-5	BCL2 binding component 3	Homo sapiens	54-58
30187811-4	2019	BENDA and BENDA + RIT increased expression of BAX and BBC3 in IGVH-MUT and IGVH-UNMUT groups, and significant differences in expression of above genes after BENDA + RIT were observed between both groups.	Bendamustine Hydrochloride	0-5	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	62-66
29695404-5	2018	Addition of either a P-gp inhibitor or a GST inhibitor, at least partly, restored sensitivity to BH in KPUM-YY1R cells.	Bendamustine Hydrochloride	97-99	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
31484887-5	2019	Further, after chemotherapy with bendamustine and rituximab, remission of both Waldenstrom"s macroglobulinemia and myelofibrosis was achieved, and TGF-beta levels normalized.	Bendamustine Hydrochloride	33-45	transforming growth factor beta 1	Homo sapiens	147-155
29986691-2	2018	This is the first study to evaluate a bendamustine-based combination regimen for the treatment of relapsed/refractory PCNSL and to characterize bendamustine pharmacokinetics in the human CSF.	Bendamustine Hydrochloride	144-156	colony stimulating factor 2	Homo sapiens	187-190
29986691-5	2018	A sparse sampling strategy and population based modeling approach was utilized for evaluation of plasma and CSF levels of bendamustine.	Bendamustine Hydrochloride	122-134	colony stimulating factor 2	Homo sapiens	108-111
29986691-12	2018	Bendamustine CSF levels are minimal; however correspond to plasma exposure and response.	Bendamustine Hydrochloride	0-12	colony stimulating factor 2	Homo sapiens	13-16
31044267-1	2019	INTRODUCTION: In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.	Bendamustine Hydrochloride	35-47	IKAROS family zinc finger 2	Homo sapiens	21-27
29695404-7	2018	CONCLUSION: BH resistance is mediated by overlapping mechanisms with overexpression of ABCB1 and MGST1, and is potentially accompanied by multidrug resistance in MCL.	Bendamustine Hydrochloride	12-14	ATP binding cassette subfamily B member 1	Homo sapiens	87-92
29695404-7	2018	CONCLUSION: BH resistance is mediated by overlapping mechanisms with overexpression of ABCB1 and MGST1, and is potentially accompanied by multidrug resistance in MCL.	Bendamustine Hydrochloride	12-14	microsomal glutathione S-transferase 1	Homo sapiens	97-102
28828689-3	2017	METHODS: In the previously completed phase 1 study RBP with a dose of 75 mg/m2 bendamustine days 1-2, prednisolone 100 mg days 1-4 and 25 mg lenalidomide days 1-21 was well tolerated.	Bendamustine Hydrochloride	79-91	SURP and G-patch domain containing 1	Homo sapiens	51-54
29983700-0	2018	Beneficial Effect of Bendamustine in a Patient with Anti-MAG/SGPG Neuropathy and Bing-Neel Syndrome Associated with Waldenstrom Macroglobulinemia: A Case Report.	Bendamustine Hydrochloride	21-33	myelin associated glycoprotein	Homo sapiens	57-60
29983700-8	2018	The present findings suggest that bendamustine monotherapy is effective not only for WM but also for its associated MAG/SGPG neuropathy and BNS.	Bendamustine Hydrochloride	34-46	myelin associated glycoprotein	Homo sapiens	116-119
29317554-1	2018	BACKGROUND: Rituximab plus bendamustine (R-B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma (FL).	Bendamustine Hydrochloride	27-39	DNA damage inducible transcript 3	Homo sapiens	182-186
29317554-12	2018	IMPLICATIONS FOR PRACTICE: Rituximab plus bendamustine (R-B) has shown to be less toxic and more effective than rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma grade 3A.	Bendamustine Hydrochloride	42-54	DNA damage inducible transcript 3	Homo sapiens	172-176
29301121-0	2018	Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.	Bendamustine Hydrochloride	90-102	C-reactive protein	Homo sapiens	50-68
29262536-3	2017	Stimulation of CLL cells via CD40 induced activation of AKT, which was closely associated with downregulation of its negative regulator PTEN, and protected CLL cells from killing by bendamustine.	Bendamustine Hydrochloride	182-194	CD40 molecule	Homo sapiens	29-33
29262536-3	2017	Stimulation of CLL cells via CD40 induced activation of AKT, which was closely associated with downregulation of its negative regulator PTEN, and protected CLL cells from killing by bendamustine.	Bendamustine Hydrochloride	182-194	AKT serine/threonine kinase 1	Homo sapiens	56-59
29181179-0	2017	Efficacy of bendamustine on thrombocytopenia and hemolytic anemia secondary to CD5-positive B-cell lymphoma with massive splenomegaly in a patient with rheumatoid arthritis.	Bendamustine Hydrochloride	12-24	CD5 molecule	Homo sapiens	79-82
28187444-6	2017	Idelalisib enhanced the bendamustine-mediated DNA damage/repair response, indicated by the phosphorylation of ATM, Chk2, and p53.	Bendamustine Hydrochloride	24-36	ATM serine/threonine kinase	Homo sapiens	110-113
28088632-2	2017	METHODS: We do so by complexation of sodium alginate and chitosan inside dioctyl sulfo succinate sodium (AOT) reverse micelles to form bendamustine hydrochloride loaded nanoparticles (CANPs).	Bendamustine Hydrochloride	135-161	calpain small subunit 1	Homo sapiens	184-189
29299182-3	2017	In this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab.	Bendamustine Hydrochloride	146-158	tumor protein p53	Homo sapiens	75-79
29299182-7	2017	In this work, bendamustine plus rituximab proved to be an effective and feasible first-line treatment strategy for elderly patients with TP53 un-mutated HCLv.	Bendamustine Hydrochloride	14-26	tumor protein p53	Homo sapiens	137-141
28314788-0	2017	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.	Bendamustine Hydrochloride	52-64	poly(ADP-ribose) polymerase 1	Homo sapiens	4-8
27655665-11	2017	Bendamustine-elicited H2AX phosphorylation was not dose-dependent, but markedly increased after fludarabine.	Bendamustine Hydrochloride	0-12	H2A.X variant histone	Homo sapiens	22-26
28187444-6	2017	Idelalisib enhanced the bendamustine-mediated DNA damage/repair response, indicated by the phosphorylation of ATM, Chk2, and p53.	Bendamustine Hydrochloride	24-36	checkpoint kinase 2	Homo sapiens	115-119
28187444-6	2017	Idelalisib enhanced the bendamustine-mediated DNA damage/repair response, indicated by the phosphorylation of ATM, Chk2, and p53.	Bendamustine Hydrochloride	24-36	tumor protein p53	Homo sapiens	125-128
28187444-10	2017	Isogenic mouse embryonic fibroblasts lacking MCL1 had higher sensitivity to bendamustine alone or in combination compared to MCL1 proficient cells.	Bendamustine Hydrochloride	76-88	myeloid cell leukemia sequence 1	Mus musculus	45-49
27500457-0	2016	Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation.	Bendamustine Hydrochloride	0-12	interleukin 10	Homo sapiens	23-37
28125678-0	2017	Inhibition of STAT3 by Anticancer Drug Bendamustine.	Bendamustine Hydrochloride	39-51	signal transducer and activator of transcription 3	Homo sapiens	14-19
28125678-3	2017	In this work, we report that BENDA inhibits signal transducer and activator of transcription 3 (STAT3).	Bendamustine Hydrochloride	29-34	signal transducer and activator of transcription 3	Homo sapiens	44-94
28125678-3	2017	In this work, we report that BENDA inhibits signal transducer and activator of transcription 3 (STAT3).	Bendamustine Hydrochloride	29-34	signal transducer and activator of transcription 3	Homo sapiens	96-101
28125678-4	2017	In an AlphaScreen-based biochemical assay using recombinant human STAT3, binding of STAT3-Src homology 2 (SH2) to the phosphotyrosine (pTyr, pY) peptide was inhibited by BENDA but not by the inactive metabolite dihydroxy bendamustine (HP2).	Bendamustine Hydrochloride	170-175	signal transducer and activator of transcription 3	Homo sapiens	66-71
28125678-4	2017	In an AlphaScreen-based biochemical assay using recombinant human STAT3, binding of STAT3-Src homology 2 (SH2) to the phosphotyrosine (pTyr, pY) peptide was inhibited by BENDA but not by the inactive metabolite dihydroxy bendamustine (HP2).	Bendamustine Hydrochloride	170-175	signal transducer and activator of transcription 3	Homo sapiens	84-89
28125678-6	2017	Furthermore, BENDA suppressed the function of cellular STAT3 as a transcriptional activator in a human breast cancer cell line, MDA-MB-468, with constitutively activated STAT3.	Bendamustine Hydrochloride	13-18	signal transducer and activator of transcription 3	Homo sapiens	55-60
28125678-6	2017	Furthermore, BENDA suppressed the function of cellular STAT3 as a transcriptional activator in a human breast cancer cell line, MDA-MB-468, with constitutively activated STAT3.	Bendamustine Hydrochloride	13-18	signal transducer and activator of transcription 3	Homo sapiens	170-175
28125678-7	2017	A competitive pull-down assay using biotinylated BENDA (Bio-BENDA) revealed that BENDA bound tightly to cellular STAT3, presumably through covalent bonds.	Bendamustine Hydrochloride	49-54	signal transducer and activator of transcription 3	Homo sapiens	113-118
28125678-7	2017	A competitive pull-down assay using biotinylated BENDA (Bio-BENDA) revealed that BENDA bound tightly to cellular STAT3, presumably through covalent bonds.	Bendamustine Hydrochloride	60-65	signal transducer and activator of transcription 3	Homo sapiens	113-118
28125678-7	2017	A competitive pull-down assay using biotinylated BENDA (Bio-BENDA) revealed that BENDA bound tightly to cellular STAT3, presumably through covalent bonds.	Bendamustine Hydrochloride	60-65	signal transducer and activator of transcription 3	Homo sapiens	113-118
28125678-8	2017	Therefore, our results suggest that the anticancer effects of BENDA may be associated, at least in part, with its inhibitory effect on the SH2 domain of STAT3.	Bendamustine Hydrochloride	62-67	signal transducer and activator of transcription 3	Homo sapiens	153-158
27293194-5	2016	The RP2D of voxtalisib in combination with rituximab or rituximab+bendamustine was 50 mg BID.	Bendamustine Hydrochloride	66-78	BH3 interacting domain death agonist	Homo sapiens	89-92
27500457-0	2016	Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation.	Bendamustine Hydrochloride	0-12	mitogen-activated protein kinase 14	Homo sapiens	65-68
27500457-4	2016	Interestingly, however, the production and secretion of interleukin-10 (IL-10) were dramatically (at least >10-fold) increased by bendamustine at growth inhibitory concentrations.	Bendamustine Hydrochloride	133-145	interleukin 10	Homo sapiens	56-70
27500457-4	2016	Interestingly, however, the production and secretion of interleukin-10 (IL-10) were dramatically (at least >10-fold) increased by bendamustine at growth inhibitory concentrations.	Bendamustine Hydrochloride	133-145	interleukin 10	Homo sapiens	72-77
27500457-5	2016	Exploration of the molecular mechanism of IL-10 production revealed that bendamustine enhanced the phosphorylation of p38 MAP kinase.	Bendamustine Hydrochloride	73-85	interleukin 10	Homo sapiens	42-47
27500457-5	2016	Exploration of the molecular mechanism of IL-10 production revealed that bendamustine enhanced the phosphorylation of p38 MAP kinase.	Bendamustine Hydrochloride	73-85	mitogen-activated protein kinase 14	Homo sapiens	118-121
27500457-6	2016	Further, Sp1 was identified as a downstream transcription factor, and the inhibition of p38 MAP kinase and Sp1 with their inhibitors led to the abrogation of bendamustine-induced IL-10 production and the DNA binding of Sp1.	Bendamustine Hydrochloride	158-170	mitogen-activated protein kinase 14	Homo sapiens	88-91
27500457-6	2016	Further, Sp1 was identified as a downstream transcription factor, and the inhibition of p38 MAP kinase and Sp1 with their inhibitors led to the abrogation of bendamustine-induced IL-10 production and the DNA binding of Sp1.	Bendamustine Hydrochloride	158-170	interleukin 10	Homo sapiens	179-184
27500457-7	2016	Importantly, when PBMC from healthy donors were cultured with bendamustine at the concentration of 30muM, under the stimulation with an anti-IgM antibody, an anti-CD40 antibody, recombinant human IL-21 (rhIL-21) and recombinant human soluble BAFF (rhsBAFF), IL-10 production by B cells (CD20+CD4-CD8-CD14-) among peripheral blood mononuclear cell (PBMC) was significantly enhanced by adding bendamustine.	Bendamustine Hydrochloride	62-74	CD40 molecule	Homo sapiens	163-167
27500457-7	2016	Importantly, when PBMC from healthy donors were cultured with bendamustine at the concentration of 30muM, under the stimulation with an anti-IgM antibody, an anti-CD40 antibody, recombinant human IL-21 (rhIL-21) and recombinant human soluble BAFF (rhsBAFF), IL-10 production by B cells (CD20+CD4-CD8-CD14-) among peripheral blood mononuclear cell (PBMC) was significantly enhanced by adding bendamustine.	Bendamustine Hydrochloride	62-74	interleukin 21	Homo sapiens	196-201
27500457-7	2016	Importantly, when PBMC from healthy donors were cultured with bendamustine at the concentration of 30muM, under the stimulation with an anti-IgM antibody, an anti-CD40 antibody, recombinant human IL-21 (rhIL-21) and recombinant human soluble BAFF (rhsBAFF), IL-10 production by B cells (CD20+CD4-CD8-CD14-) among peripheral blood mononuclear cell (PBMC) was significantly enhanced by adding bendamustine.	Bendamustine Hydrochloride	62-74	TNF superfamily member 13b	Homo sapiens	242-246
27500457-7	2016	Importantly, when PBMC from healthy donors were cultured with bendamustine at the concentration of 30muM, under the stimulation with an anti-IgM antibody, an anti-CD40 antibody, recombinant human IL-21 (rhIL-21) and recombinant human soluble BAFF (rhsBAFF), IL-10 production by B cells (CD20+CD4-CD8-CD14-) among peripheral blood mononuclear cell (PBMC) was significantly enhanced by adding bendamustine.	Bendamustine Hydrochloride	62-74	interleukin 10	Homo sapiens	258-263
27500457-7	2016	Importantly, when PBMC from healthy donors were cultured with bendamustine at the concentration of 30muM, under the stimulation with an anti-IgM antibody, an anti-CD40 antibody, recombinant human IL-21 (rhIL-21) and recombinant human soluble BAFF (rhsBAFF), IL-10 production by B cells (CD20+CD4-CD8-CD14-) among peripheral blood mononuclear cell (PBMC) was significantly enhanced by adding bendamustine.	Bendamustine Hydrochloride	62-74	keratin 20	Homo sapiens	287-291
27500457-7	2016	Importantly, when PBMC from healthy donors were cultured with bendamustine at the concentration of 30muM, under the stimulation with an anti-IgM antibody, an anti-CD40 antibody, recombinant human IL-21 (rhIL-21) and recombinant human soluble BAFF (rhsBAFF), IL-10 production by B cells (CD20+CD4-CD8-CD14-) among peripheral blood mononuclear cell (PBMC) was significantly enhanced by adding bendamustine.	Bendamustine Hydrochloride	62-74	CD14 molecule	Homo sapiens	300-304
27500457-8	2016	These results collectively suggest that the p38 MAP kinase-Sp1 pathway plays a crucial role in bendamustine-induced IL-10 production by B cells.	Bendamustine Hydrochloride	95-107	mitogen-activated protein kinase 14	Homo sapiens	44-47
27500457-8	2016	These results collectively suggest that the p38 MAP kinase-Sp1 pathway plays a crucial role in bendamustine-induced IL-10 production by B cells.	Bendamustine Hydrochloride	95-107	interleukin 10	Homo sapiens	116-121
27120083-2	2016	The aim of the study was to evaluate the pharmacokinetics of bendamustine and its key cytochrome P 450 (CYP) 1A2 mediated gamma-hydroxybendamustine (M3) metabolite after 30- and 60-min intravenous infusion of bendamustine in rats.	Bendamustine Hydrochloride	61-73	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	86-112
27245314-0	2016	Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM kappa and IgM lambda: Case Report and Review of the Literature.	Bendamustine Hydrochloride	115-127	myelin associated glycoprotein	Homo sapiens	5-35
27120083-2	2016	The aim of the study was to evaluate the pharmacokinetics of bendamustine and its key cytochrome P 450 (CYP) 1A2 mediated gamma-hydroxybendamustine (M3) metabolite after 30- and 60-min intravenous infusion of bendamustine in rats.	Bendamustine Hydrochloride	135-147	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	86-112
26196503-3	2015	Especially basic esters, which are positively charged under physiological conditions, were in the crystal violet and the MTT assay up to approximately 100 times more effective than bendamustine, paralleled by a higher fraction of early apoptotic cancer cells and increased expression of p53.	Bendamustine Hydrochloride	181-193	tumor protein p53	Homo sapiens	287-290
27103007-2	2016	Recently, the StiL and the BRIGHT trials showed that the combination of rituximab and bendamustine (R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a better toxicity profile.	Bendamustine Hydrochloride	86-98	STIL centriolar assembly protein	Homo sapiens	14-18
27103007-2	2016	Recently, the StiL and the BRIGHT trials showed that the combination of rituximab and bendamustine (R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a better toxicity profile.	Bendamustine Hydrochloride	86-98	DNA damage inducible transcript 3	Homo sapiens	197-201
26581069-12	2016	After a new BMB showing 80% of monotypic kappa PCs, a LCE relapse was diagnosed and the patient started the treatment with bendamustine, bortezomib and dexamethasone.	Bendamustine Hydrochloride	123-135	ELOVL fatty acid elongase 6	Homo sapiens	54-57
26701728-0	2016	CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.	Bendamustine Hydrochloride	49-61	CD69 molecule	Homo sapiens	0-4
26701728-3	2016	We observed that mRNA expression of CD69 (CD69) and ITGAM (CD11b) constitute the most powerful predictor of response to bendamustine.	Bendamustine Hydrochloride	120-132	CD69 molecule	Homo sapiens	36-40
26701728-3	2016	We observed that mRNA expression of CD69 (CD69) and ITGAM (CD11b) constitute the most powerful predictor of response to bendamustine.	Bendamustine Hydrochloride	120-132	CD69 molecule	Homo sapiens	42-46
26701728-3	2016	We observed that mRNA expression of CD69 (CD69) and ITGAM (CD11b) constitute the most powerful predictor of response to bendamustine.	Bendamustine Hydrochloride	120-132	integrin subunit alpha M	Homo sapiens	52-57
26701728-3	2016	We observed that mRNA expression of CD69 (CD69) and ITGAM (CD11b) constitute the most powerful predictor of response to bendamustine.	Bendamustine Hydrochloride	120-132	integrin subunit alpha M	Homo sapiens	59-64
26701728-4	2016	When we interrogated the predictive value of the corresponding cell surface proteins, the expression of the activation marker CD69 was the most reliable predictor of sensitivity to bendamustine.	Bendamustine Hydrochloride	181-193	CD69 molecule	Homo sapiens	126-130
26701728-6	2016	We also showed that when CLL cells were co-cultured with distinct subtypes of stromal cells, an upregulation of CD69 was accompanied by a reduced sensitivity to bendamustine.	Bendamustine Hydrochloride	161-173	CD69 molecule	Homo sapiens	112-116
26701728-8	2016	Furthermore, pretreatment of CD69 high CLL cases with the B-cell receptor (BCR) pathway inhibitors ibrutinib and idelalisib decreased CD69 levels and enhanced bendamustine cytotoxic effect.	Bendamustine Hydrochloride	159-171	CD69 molecule	Homo sapiens	29-33
26701728-9	2016	Collectively, our findings indicate that CD69 could be a predictor of bendamustine response in CLL patients and the combination of clinically-tested BCR signaling inhibitors with bendamustine may represent a promising strategy for bendamustine low responsive CLL cases.	Bendamustine Hydrochloride	70-82	CD69 molecule	Homo sapiens	41-45
25582574-0	2015	Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.	Bendamustine Hydrochloride	60-72	solute carrier family 22 member 1	Homo sapiens	6-34
25582574-0	2015	Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.	Bendamustine Hydrochloride	60-72	solute carrier family 22 member 1	Homo sapiens	36-41
25582574-4	2015	Our results showed that hOCT1 is a bendamustine transporter, as bendamustine could cis-inhibit the uptake of a canonical hOCT1 substrate, with a Ki in the micromolar range, consistent with the EC50 values of the cytotoxicity triggered by this drug in HEK293 cells expressing hOCT1.	Bendamustine Hydrochloride	35-47	solute carrier family 22 member 1	Homo sapiens	24-29
25582574-4	2015	Our results showed that hOCT1 is a bendamustine transporter, as bendamustine could cis-inhibit the uptake of a canonical hOCT1 substrate, with a Ki in the micromolar range, consistent with the EC50 values of the cytotoxicity triggered by this drug in HEK293 cells expressing hOCT1.	Bendamustine Hydrochloride	35-47	solute carrier family 22 member 1	Homo sapiens	121-126
25582574-4	2015	Our results showed that hOCT1 is a bendamustine transporter, as bendamustine could cis-inhibit the uptake of a canonical hOCT1 substrate, with a Ki in the micromolar range, consistent with the EC50 values of the cytotoxicity triggered by this drug in HEK293 cells expressing hOCT1.	Bendamustine Hydrochloride	35-47	solute carrier family 22 member 1	Homo sapiens	121-126
25582574-5	2015	hOCT1 polymorphic variants determining impaired bendamustine-transporter interaction, consistently reduced bendamustine cytotoxicity in HEK293 cells stably expressing them.	Bendamustine Hydrochloride	48-60	solute carrier family 22 member 1	Homo sapiens	0-5
25582574-7	2015	Ex vivo cytotoxicity to bendamustine was measured in a subset of cases and shown to correlate with SLC22A1 polymorphic variants.	Bendamustine Hydrochloride	24-36	solute carrier family 22 member 1	Homo sapiens	99-106
25477469-6	2015	Bendamustine inhibited only OAT3-mediated ES uptake, which was reduced down to 14.3% of control cells, suggesting that it interacts exclusively with OAT3.	Bendamustine Hydrochloride	0-12	solute carrier family 22 member 8	Homo sapiens	28-32
25833722-0	2015	Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine.	Bendamustine Hydrochloride	119-131	CD8a molecule	Homo sapiens	31-34
25833722-8	2015	It is speculated that inappropriate activation of CD8(+) T cells by latently infected pathogens may be one of the triggers of late-onset skin reactions caused by bendamustine.	Bendamustine Hydrochloride	162-174	CD8a molecule	Homo sapiens	50-53
25975443-8	2015	Randomized clinical trials have (a) established that bendamustine-rituximab (BR) is more efficacious and less toxic than rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); (b) established that bortezomib should replace vincristine if using an R-CHOP backbone; and (c) established that maintenance rituximab (MR) is beneficial after an R-CHOP induction.	Bendamustine Hydrochloride	53-65	DNA damage inducible transcript 3	Homo sapiens	194-198
25975443-8	2015	Randomized clinical trials have (a) established that bendamustine-rituximab (BR) is more efficacious and less toxic than rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); (b) established that bortezomib should replace vincristine if using an R-CHOP backbone; and (c) established that maintenance rituximab (MR) is beneficial after an R-CHOP induction.	Bendamustine Hydrochloride	53-65	DNA damage inducible transcript 3	Homo sapiens	274-278
25975443-8	2015	Randomized clinical trials have (a) established that bendamustine-rituximab (BR) is more efficacious and less toxic than rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); (b) established that bortezomib should replace vincristine if using an R-CHOP backbone; and (c) established that maintenance rituximab (MR) is beneficial after an R-CHOP induction.	Bendamustine Hydrochloride	53-65	DNA damage inducible transcript 3	Homo sapiens	274-278
25663907-0	2015	Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab.	Bendamustine Hydrochloride	123-135	translocator protein	Homo sapiens	19-39
25663907-4	2015	In the present study, the response of 30 consecutive chronic lymphocytic leukemia (CLL) patients to bendamustine and rituximab treatment was evaluated according to TSPO expression levels.	Bendamustine Hydrochloride	100-112	translocator protein	Homo sapiens	164-168
25477469-0	2015	Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake.	Bendamustine Hydrochloride	90-102	solute carrier family 22 member 8	Homo sapiens	12-39
25829094-9	2015	Minor involvement of CYP1A2 in bendamustine elimination suggests a low likelihood of drug-drug interactions with CYP1A2 inhibitors.	Bendamustine Hydrochloride	31-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	21-27
25829094-9	2015	Minor involvement of CYP1A2 in bendamustine elimination suggests a low likelihood of drug-drug interactions with CYP1A2 inhibitors.	Bendamustine Hydrochloride	31-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	113-119
25477469-4	2015	We examined the effects of structural analogs of p-aminohippurate (PAH), melphalan, chlorambucil, and bendamustine, on OAT1-mediated [(3)H]PAH uptake and OAT3- and OAT4-mediated [(3)H]estrone sulfate (ES) uptake in stably transfected human embryonic kidney-293 cells.	Bendamustine Hydrochloride	102-114	solute carrier family 22 member 6	Homo sapiens	119-123
25477469-6	2015	Bendamustine inhibited only OAT3-mediated ES uptake, which was reduced down to 14.3% of control cells, suggesting that it interacts exclusively with OAT3.	Bendamustine Hydrochloride	0-12	solute carrier family 22 member 8	Homo sapiens	149-153
25477469-9	2015	OAT3-mediated accumulation of bendamustine was associated with reduced cell proliferation and an increased rate of apoptosis.	Bendamustine Hydrochloride	30-42	solute carrier family 22 member 8	Homo sapiens	0-4
25477469-10	2015	We conclude that the high efficacy of bendamustine in treating CLL might be partly contributed to the expression of OAT3 in lymphoma cells and the high affinity of bendamustine for this transporter.	Bendamustine Hydrochloride	38-50	solute carrier family 22 member 8	Homo sapiens	116-120
24951124-4	2014	To evaluate the effects of bendamustine-rituximab and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on the recuperation of immune system, we analyze the distribution of CD4+ and CD8+ T cells, B cells, and NK cells in peripheral blood of 18 patients who received 4-6 cycles of rituximab-bendamustine (BR) or six R-CHOP before therapy and 6 months after completing treatment.	Bendamustine Hydrochloride	27-39	DNA damage inducible transcript 3	Homo sapiens	131-135
24912431-8	2015	Last, CXCR4(S338X) WM cells showed varying levels of resistance to other WM relevant therapeutics, including bendamustine, fludarabine, bortezomib and idelalisib in the presence of SDF-1a.	Bendamustine Hydrochloride	109-121	C-X-C motif chemokine receptor 4	Homo sapiens	6-11
25705531-0	2015	Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.	Bendamustine Hydrochloride	95-107	PML nuclear body scaffold	Homo sapiens	19-22
25705531-4	2015	We report the case of a 66-year-old woman who developed PML a year after completion of therapy with rituximab, ibritumomab, and bendamustine.	Bendamustine Hydrochloride	128-140	PML nuclear body scaffold	Homo sapiens	56-59
25481222-5	2015	Whereas NTCP did not show any strong interactions with the cytostatics tested, we observed a very strong inhibition of OAT2 mediated [(3)H] cGMP uptake in the presence of bendamustine, irinotecan and paclitaxel.	Bendamustine Hydrochloride	171-183	solute carrier family 22 member 7	Homo sapiens	119-123
25481222-6	2015	The Ki values of OAT2 for bendamustine, irinotecan and paclitaxel were determined to be 43.3+-4.33muM, 26.4+-2.34muM and 10.4+-0.45muM, respectively.	Bendamustine Hydrochloride	26-38	solute carrier family 22 member 7	Homo sapiens	17-21
25481222-7	2015	Incubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.	Bendamustine Hydrochloride	14-26	solute carrier family 22 member 7	Homo sapiens	32-36
25481222-7	2015	Incubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.	Bendamustine Hydrochloride	14-26	solute carrier family 22 member 7	Homo sapiens	260-264
25481222-7	2015	Incubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.	Bendamustine Hydrochloride	152-164	solute carrier family 22 member 7	Homo sapiens	32-36
25481222-7	2015	Incubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.	Bendamustine Hydrochloride	152-164	solute carrier family 22 member 7	Homo sapiens	260-264
25481222-7	2015	Incubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.	Bendamustine Hydrochloride	152-164	solute carrier family 22 member 7	Homo sapiens	32-36
25481222-7	2015	Incubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.	Bendamustine Hydrochloride	152-164	solute carrier family 22 member 7	Homo sapiens	260-264
25133896-0	2014	Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.	Bendamustine Hydrochloride	11-23	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	136-140
24111951-0	2014	Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.	Bendamustine Hydrochloride	122-134	AKT serine/threonine kinase 1	Homo sapiens	0-3
24308434-0	2014	Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.	Bendamustine Hydrochloride	0-12	tumor protein p53	Homo sapiens	121-124
24398467-0	2014	Competitive interactions of anti-carcinogens with serum albumin: a spectroscopic study of bendamustine and dexamethasone with the aid of chemometrics.	Bendamustine Hydrochloride	90-102	albumin	Homo sapiens	50-63
24398467-1	2014	Interactions between the anti-carcinogens, bendamustine (BDM) and dexamethasone (DXM), with bovine serum albumin (BSA) were investigated with the use of fluorescence and UV-vis spectroscopies under pseudo-physiological conditions (Tris-HCl buffer, pH 7.4).	Bendamustine Hydrochloride	43-55	albumin	Homo sapiens	99-112
24398467-1	2014	Interactions between the anti-carcinogens, bendamustine (BDM) and dexamethasone (DXM), with bovine serum albumin (BSA) were investigated with the use of fluorescence and UV-vis spectroscopies under pseudo-physiological conditions (Tris-HCl buffer, pH 7.4).	Bendamustine Hydrochloride	57-60	albumin	Homo sapiens	99-112
24681707-8	2014	Hsp32-targeting drugs were found to synergize with imatinib, nilotinib, and bendamustine in producing growth inhibition and apoptosis in Ph+ ALL cells.	Bendamustine Hydrochloride	76-88	heme oxygenase 1	Homo sapiens	0-5
24626203-6	2014	Furthermore, bendamustine increased the expression of ENT1 at both mRNA and protein levels and enhanced the uptake of Ara-C and subsequent increase in Ara-C triphosphate (Ara-CTP) in HBL-2 cells to an extent comparable with the purine analog fludarabine.	Bendamustine Hydrochloride	13-25	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	54-58
23692564-9	2013	In conclusion, RBP with lenalidomide 25 mg/d, days 1-21 and bendamustine 75 mg/m(2) days 1-2 is well tolerated in patients with relapsed/refractory MM.	Bendamustine Hydrochloride	60-72	SURP and G-patch domain containing 1	Homo sapiens	15-18
23688587-9	2013	Our results demonstrate a network of regulatory factors that may contribute to the synergistic cytotoxicity of everolimus and bendamustine, and provide a rationale for application for the combinatorial treatment of MM with alkylating agents and mTOR inhibitors in future clinical practice.	Bendamustine Hydrochloride	126-138	mechanistic target of rapamycin kinase	Homo sapiens	245-249
24344029-8	2013	CONCLUSION: These results implicate PDIA3 and CPIN1 as potential molecular targets for drug intervention in MM and thus provide novel insights into the mechanisms of antitumor activity of bendamustine.	Bendamustine Hydrochloride	188-200	protein disulfide isomerase family A member 3	Homo sapiens	36-41
24344029-8	2013	CONCLUSION: These results implicate PDIA3 and CPIN1 as potential molecular targets for drug intervention in MM and thus provide novel insights into the mechanisms of antitumor activity of bendamustine.	Bendamustine Hydrochloride	188-200	cytokine induced apoptosis inhibitor 1	Homo sapiens	46-51
23986050-0	2013	[Bendamustine-rituximab therapy is effective for transformed follicular lymphoma with significant expression of p53].	Bendamustine Hydrochloride	1-13	tumor protein p53	Homo sapiens	112-115
23986050-9	2013	Subsequently, she was treated with five courses of BR therapy, because bendamustine had been reported to be effective for p53 gene-deficient B cell neoplasms.	Bendamustine Hydrochloride	71-83	tumor protein p53	Homo sapiens	122-125
23459296-5	2013	An apoptotic-ELISA and western blot assays on PARP cleavage and caspase-8 and caspase-3 revealed that bendamustine in combination with entinostat exhibited a much more potent activity than either agent alone to promote the MM cells undergoing apoptosis in a dose-dependent manner.	Bendamustine Hydrochloride	102-114	collagen type XI alpha 2 chain	Homo sapiens	46-50
23459296-5	2013	An apoptotic-ELISA and western blot assays on PARP cleavage and caspase-8 and caspase-3 revealed that bendamustine in combination with entinostat exhibited a much more potent activity than either agent alone to promote the MM cells undergoing apoptosis in a dose-dependent manner.	Bendamustine Hydrochloride	102-114	caspase 8	Homo sapiens	64-73
23459296-5	2013	An apoptotic-ELISA and western blot assays on PARP cleavage and caspase-8 and caspase-3 revealed that bendamustine in combination with entinostat exhibited a much more potent activity than either agent alone to promote the MM cells undergoing apoptosis in a dose-dependent manner.	Bendamustine Hydrochloride	102-114	caspase 3	Homo sapiens	78-87
23459296-7	2013	Furthermore, studies on DNA damage response indicated that phospho-histone H2A.X (P-H2A.X), a hall marker of DNA double strand break, along with phosphorylated CHK2 (P-CHK2) was significantly enhanced by the combinations of bendamustine and entinostat as compared to either agent alone.	Bendamustine Hydrochloride	224-236	checkpoint kinase 2	Homo sapiens	160-164
23430121-9	2013	CONCLUSIONS: Combination therapy with bendamustine and erlotinib causes excessive toxicity with severe, prolonged lymphopenia, depressed CD4 counts, and opportunistic infections and should not be pursued further.	Bendamustine Hydrochloride	38-50	CD4 molecule	Homo sapiens	137-140
23380051-7	2013	In these cells, both Aurora kinase A (AURKA) and Polo-like kinase-1 (PLK-1), key components of the spindle-assembly checkpoint, were down-regulated following incubation with bendamustine, whereas levels of Cyclin B1 increased as a consequence of the prolonged mitotic arrest induced by the drug.	Bendamustine Hydrochloride	174-186	aurora kinase A	Homo sapiens	21-36
23380051-7	2013	In these cells, both Aurora kinase A (AURKA) and Polo-like kinase-1 (PLK-1), key components of the spindle-assembly checkpoint, were down-regulated following incubation with bendamustine, whereas levels of Cyclin B1 increased as a consequence of the prolonged mitotic arrest induced by the drug.	Bendamustine Hydrochloride	174-186	aurora kinase A	Homo sapiens	38-43
23380051-7	2013	In these cells, both Aurora kinase A (AURKA) and Polo-like kinase-1 (PLK-1), key components of the spindle-assembly checkpoint, were down-regulated following incubation with bendamustine, whereas levels of Cyclin B1 increased as a consequence of the prolonged mitotic arrest induced by the drug.	Bendamustine Hydrochloride	174-186	polo like kinase 1	Homo sapiens	49-67
23380051-7	2013	In these cells, both Aurora kinase A (AURKA) and Polo-like kinase-1 (PLK-1), key components of the spindle-assembly checkpoint, were down-regulated following incubation with bendamustine, whereas levels of Cyclin B1 increased as a consequence of the prolonged mitotic arrest induced by the drug.	Bendamustine Hydrochloride	174-186	polo like kinase 1	Homo sapiens	69-74
23390564-11	2013	Either cladribine or bendamustine led to a remarkable increase of the phosphorylated H2A.X, CHK1 and CHK2 in both MM1.S and MM1.R cells, suggesting an induction of DNA damage response.	Bendamustine Hydrochloride	21-33	H2A.X variant histone	Homo sapiens	85-90
23380051-7	2013	In these cells, both Aurora kinase A (AURKA) and Polo-like kinase-1 (PLK-1), key components of the spindle-assembly checkpoint, were down-regulated following incubation with bendamustine, whereas levels of Cyclin B1 increased as a consequence of the prolonged mitotic arrest induced by the drug.	Bendamustine Hydrochloride	174-186	cyclin B1	Homo sapiens	206-215
23390564-5	2013	MTS-based proliferation assays showed that cladribine and bendamustine exhibited similar anti-proliferation/anti-survival effects on MM1.S and MM1.R cells in a dose-dependent manner.	Bendamustine Hydrochloride	58-70	plexin B2	Homo sapiens	133-136
23450436-2	2013	The combination of bendamustine and cytarabine has demonstrated distinct and synergistic mechanisms of action in preclinical studies on cell lines and primary tumor cells of several B-cell lymphomas, including 17p deleted or TP53 mutated CLL.	Bendamustine Hydrochloride	19-31	tumor protein p53	Homo sapiens	225-229
23390564-5	2013	MTS-based proliferation assays showed that cladribine and bendamustine exhibited similar anti-proliferation/anti-survival effects on MM1.S and MM1.R cells in a dose-dependent manner.	Bendamustine Hydrochloride	58-70	plexin B2	Homo sapiens	143-146
23390564-11	2013	Either cladribine or bendamustine led to a remarkable increase of the phosphorylated H2A.X, CHK1 and CHK2 in both MM1.S and MM1.R cells, suggesting an induction of DNA damage response.	Bendamustine Hydrochloride	21-33	checkpoint kinase 1	Homo sapiens	92-96
23390564-7	2013	The IC50s of bendamustine were approximately 119.8 mumol/L (MM1.S) and 138 mumol/L (MM1.R).	Bendamustine Hydrochloride	13-25	plexin B2	Homo sapiens	60-63
23390564-7	2013	The IC50s of bendamustine were approximately 119.8 mumol/L (MM1.S) and 138 mumol/L (MM1.R).	Bendamustine Hydrochloride	13-25	plexin B2	Homo sapiens	84-87
23390564-11	2013	Either cladribine or bendamustine led to a remarkable increase of the phosphorylated H2A.X, CHK1 and CHK2 in both MM1.S and MM1.R cells, suggesting an induction of DNA damage response.	Bendamustine Hydrochloride	21-33	checkpoint kinase 2	Homo sapiens	101-105
23390564-8	2013	An apoptotic-ELISA and western blot assays of PARP cleavage and activation of caspase-8 and caspase-3 indicated that cladribine or bendamustine induced apoptosis in both cell lines.	Bendamustine Hydrochloride	131-143	collagen type XI alpha 2 chain	Homo sapiens	46-50
23390564-11	2013	Either cladribine or bendamustine led to a remarkable increase of the phosphorylated H2A.X, CHK1 and CHK2 in both MM1.S and MM1.R cells, suggesting an induction of DNA damage response.	Bendamustine Hydrochloride	21-33	plexin B2	Homo sapiens	114-117
23390564-8	2013	An apoptotic-ELISA and western blot assays of PARP cleavage and activation of caspase-8 and caspase-3 indicated that cladribine or bendamustine induced apoptosis in both cell lines.	Bendamustine Hydrochloride	131-143	caspase 8	Homo sapiens	78-87
23390564-8	2013	An apoptotic-ELISA and western blot assays of PARP cleavage and activation of caspase-8 and caspase-3 indicated that cladribine or bendamustine induced apoptosis in both cell lines.	Bendamustine Hydrochloride	131-143	caspase 3	Homo sapiens	92-101
23390564-11	2013	Either cladribine or bendamustine led to a remarkable increase of the phosphorylated H2A.X, CHK1 and CHK2 in both MM1.S and MM1.R cells, suggesting an induction of DNA damage response.	Bendamustine Hydrochloride	21-33	plexin B2	Homo sapiens	124-127
22653969-5	2012	The Chk1/2 inhibitor AZD7762 potentiated the antiproliferative effects of bendamustine, melphalan, and doxorubicin but not bortezomib in multiple myeloma cell lines that were p53-deficient.	Bendamustine Hydrochloride	74-86	checkpoint kinase 1	Homo sapiens	4-8
22624727-6	2012	Bendamustine activated p53 in Granta 519 tumours, concurrent with activation of caspase 3.	Bendamustine Hydrochloride	0-12	tumor protein p53	Homo sapiens	23-26
22653969-8	2012	In summary, the cytotoxic effects of bendamustine, melphalan and doxorubicin on p53-deficient multiple myeloma cell lines were enhanced by the coadministration of AZD7762.	Bendamustine Hydrochloride	37-49	tumor protein p53	Homo sapiens	80-83
21454214-13	2011	Bendamustine is active and produces durable responses in previously treated WM, both as monotherapy and with CD20-directed monoclonal antibodies.	Bendamustine Hydrochloride	0-12	keratin 20	Homo sapiens	109-113
21624007-2	2011	The present dose-escalation study evaluated the safety, efficacy, and pharmacokinetics of bendamustine hydrochloride in combination with rituximab in patients with relapsed/refractory, CD20-positive, aggressive B-NHL.	Bendamustine Hydrochloride	90-116	keratin 20	Homo sapiens	185-189
21530768-4	2011	The increased potency of bendamustine may be due to secondary mechanisms such as inhibition of mitotic checkpoints, inefficient DNA repair, and initiation of p53-dependent DNA-damage stress response, all of which lead to mitotic catastrophe and apoptosis.	Bendamustine Hydrochloride	25-37	tumor protein p53	Homo sapiens	158-161
22347385-5	2012	CD138(+) myeloma cells in the BM were reduced by p53-dependent apoptosis following administration of the nitrogen mustard derivative bendamustine to mice in the NOG-hMM model.	Bendamustine Hydrochloride	133-145	transformation related protein 53, pseudogene	Mus musculus	49-52
21257672-11	2011	All other grade 3 and 4 hematotoxicities and non-hematological toxic effects ranged between 2% and 11% CONCLUSIONS: Because of its efficacy and low toxicity, bendamustine in combination with rituximab may be an alternative treatment for aggressive lymphomas in old patients not eligible for R-CHOP.	Bendamustine Hydrochloride	158-170	DNA damage inducible transcript 3	Homo sapiens	293-297
17653574-0	2008	Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.	Bendamustine Hydrochloride	0-12	ATM serine/threonine kinase	Homo sapiens	86-89
19263299-0	2009	Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53.	Bendamustine Hydrochloride	0-12	tumor protein p53	Homo sapiens	111-114
18980985-0	2008	Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.	Bendamustine Hydrochloride	0-12	tumor protein p53	Homo sapiens	29-32
18980985-6	2008	Bendamustine was found to act synergistically with nucleoside analogues in both CLL and MCL, this combination being effective in p53 mutated cases resistant to standard chemotherapy.	Bendamustine Hydrochloride	0-12	tumor protein p53	Homo sapiens	129-132
18980985-8	2008	CONCLUSIONS: Our findings support the use of bendamustine as a therapeutic agent, alone or in combination, for CLL and MCL with p53 alterations and describe the molecular basis of its activity in these entities.	Bendamustine Hydrochloride	45-57	tumor protein p53	Homo sapiens	128-131
18716777-1	2009	PURPOSE: The aim of the RiTa trial is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule in anthracycline pre-treated metastatic breast cancer patients.	Bendamustine Hydrochloride	77-89	RBPJ interacting and tubulin associated 1	Homo sapiens	24-28
17653574-15	2008	CONCLUSION: Bendamustine induces ATM-Chk2-Cdc2-mediated G2 arrest and p53 mediated apoptosis.	Bendamustine Hydrochloride	12-24	tumor protein p53	Homo sapiens	70-73
17653574-16	2008	Inhibition of p38 MAPK augments apoptosis and abrogates G2 arrest and can be considered as a new therapeutic strategy in combination with bendamustine.	Bendamustine Hydrochloride	138-150	mitogen-activated protein kinase 14	Homo sapiens	14-17
17653574-0	2008	Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.	Bendamustine Hydrochloride	0-12	checkpoint kinase 2	Homo sapiens	90-94
17653574-0	2008	Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.	Bendamustine Hydrochloride	0-12	cell division cycle 25A	Homo sapiens	95-101
17653574-0	2008	Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.	Bendamustine Hydrochloride	0-12	ATM serine/threonine kinase	Homo sapiens	106-109
17653574-0	2008	Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.	Bendamustine Hydrochloride	0-12	tumor protein p53	Homo sapiens	110-113
17653574-0	2008	Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.	Bendamustine Hydrochloride	0-12	H3 histone pseudogene 16	Homo sapiens	114-117
17653574-7	2008	RESULTS: We show that bendamustine induces apoptosis with an IC50 of 35-65 mug/ml and with cleavage of caspase 3.	Bendamustine Hydrochloride	22-34	caspase 3	Homo sapiens	103-112
17653574-13	2008	Targeting of p38 MAPK by the selective inhibitor SB202190 significantly increases bendamustine induced apoptosis.	Bendamustine Hydrochloride	82-94	mitogen-activated protein kinase 14	Homo sapiens	13-16
17653574-15	2008	CONCLUSION: Bendamustine induces ATM-Chk2-Cdc2-mediated G2 arrest and p53 mediated apoptosis.	Bendamustine Hydrochloride	12-24	ATM serine/threonine kinase	Homo sapiens	33-36
17653574-15	2008	CONCLUSION: Bendamustine induces ATM-Chk2-Cdc2-mediated G2 arrest and p53 mediated apoptosis.	Bendamustine Hydrochloride	12-24	checkpoint kinase 2	Homo sapiens	37-41
17653574-15	2008	CONCLUSION: Bendamustine induces ATM-Chk2-Cdc2-mediated G2 arrest and p53 mediated apoptosis.	Bendamustine Hydrochloride	12-24	cyclin dependent kinase 1	Homo sapiens	42-46
17414628-10	2007	Mean pharmacokinetic parameters of bendamustine hydrochloride were a tmax of 32.3 min, a t1/2 of 37.8 min, a volume of distribution of 14.2 l/m and a clearance of 287.8 ml/min/m2.	Bendamustine Hydrochloride	35-61	interleukin 1 receptor like 1	Homo sapiens	89-101
12756557-13	2003	CONCLUSION: Bendamustine is capable of inducing a reduction in CD4(+) lymphocyte counts causing a severe T-lymphocyte-mediated immunosuppression.	Bendamustine Hydrochloride	12-24	CD4 molecule	Homo sapiens	63-66
16088404-7	2006	CONCLUSIONS: Bendamustine can efficaciously and safely replace cyclophosphamide, as used in standard COP therapy, for the treatment of patients with indolent NHL and mantle cell lymphoma.	Bendamustine Hydrochloride	13-25	caspase recruitment domain family member 16	Homo sapiens	101-104
15621757-0	2004	Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies.	Bendamustine Hydrochloride	0-12	keratin 20	Homo sapiens	134-138
15621757-2	2004	We have developed a new chemoimmunotherapy for patients with relapsed or refractory CD20-positive indolent lymphomas and CLL by combining the chemotherapeutic agents Bendamustine (B) and Mitoxantrone (M) with the monoclonal antibody Rituximab.	Bendamustine Hydrochloride	166-178	keratin 20	Homo sapiens	84-88
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	cytochrome c, somatic	Homo sapiens	190-202
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	diablo IAP-binding mitochondrial protein	Homo sapiens	207-211
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	diablo IAP-binding mitochondrial protein	Homo sapiens	212-218
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	X-linked inhibitor of apoptosis	Homo sapiens	242-273
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	X-linked inhibitor of apoptosis	Homo sapiens	275-279
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	baculoviral IAP repeat containing 2	Homo sapiens	282-287
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	pro-apoptotic WT1 regulator	Homo sapiens	289-294
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	death domain associated protein	Homo sapiens	299-303
12948851-7	2003	By using the IC(50) (dosages causing 50% rate of apoptosis) the synergistic effect of the combination of bendamustine and cladribine was associated with an enhanced mitochondrial release of cytochrome c and Smac/DIABLO, by down-regulation of x-linked inhibitor of apoptosis (XIAP), cIAP1, Par-4 and Daxx as well as by a significantly increased activation of caspases-3, -6, -7, -8 and -9.	Bendamustine Hydrochloride	105-117	caspase 3	Homo sapiens	358-387
12756557-14	2003	Measuring CD4(+) lymphocyte counts may be helpful in determining the risk of PCP in patients treated with bendamustine.	Bendamustine Hydrochloride	106-118	CD4 molecule	Homo sapiens	10-13
34743203-6	2022	Besides, in vitro and in vivo studies indicated that PTGDS knockdown and AT56 treatment exerted an anti-tumor effect by regulating cell viability, proliferation, apoptosis, cell cycle, and invasion, and enhanced the drug sensitivity to adriamycin and bendamustine through promoting DNA damage.	Bendamustine Hydrochloride	251-263	prostaglandin D2 synthase	Homo sapiens	53-58
12029443-5	2002	RESULTS: Bendamustine was preferably active against leukemic cells of lymphoid origin and was found to induce apoptosis in SKW-3 and BV-173 cells as shown by oligonucleosomal DNA and nuclear fragmentation, PARP cleavage, and formation of a sub-G1 fraction.	Bendamustine Hydrochloride	9-21	poly(ADP-ribose) polymerase 1	Homo sapiens	206-210
11206271-17	2001	A general feature was the decline of the CD4/CD8 ratio: mean before therapy: 1.36; after two courses: 0.98; after four courses: 0.6, as documented in all patients who received at least two courses of bendamustine (n = 12).	Bendamustine Hydrochloride	200-212	CD4 molecule	Homo sapiens	41-44
11206271-17	2001	A general feature was the decline of the CD4/CD8 ratio: mean before therapy: 1.36; after two courses: 0.98; after four courses: 0.6, as documented in all patients who received at least two courses of bendamustine (n = 12).	Bendamustine Hydrochloride	200-212	CD8a molecule	Homo sapiens	45-48
34467833-0	2022	CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.	Bendamustine Hydrochloride	88-100	CD5 molecule	Homo sapiens	0-3
34467833-5	2022	CD5-positive MZL may have a propensity to leukemic dissemination, histologic transformation, and may derive benefit from first-line bendamustine/rituximab rather than rituximab alone.	Bendamustine Hydrochloride	132-144	CD5 molecule	Homo sapiens	0-3
11410411-11	2001	The antagonism of the combination of bendamustine and anthracyclines appeared to be due to inhibition of depolarization of mitochondrial-membrane potential and caspase-3-activity during apoptosis of the studied cell lines.	Bendamustine Hydrochloride	37-49	caspase 3	Homo sapiens	160-169
35301681-9	2022	In SU-DHL-4-OR-18-8 tumors, bendamustine treatment increased phospho-IRE1 on Day 4 and intratumor NK cells/macrophages on Day 10.	Bendamustine Hydrochloride	28-40	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	69-73
34334330-0	2021	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.	Bendamustine Hydrochloride	122-134	chaperonin containing TCP1 subunit 3	Homo sapiens	81-85
34334330-1	2021	INTRODUCTION: The Alliance A041202/CCTG CLC.2 trial demonstrated superior progression-free survival with ibrutinib-based therapy compared to chemoimmunotherapy with bendamustine-rituximab (BR) in previously untreated older patients with chronic lymphocytic leukemia.	Bendamustine Hydrochloride	165-177	chaperonin containing TCP1 subunit 3	Homo sapiens	35-39
34690088-5	2022	The combination of brentuximab vedotin and bendamustine (BVB) is a promising treatment for patients with R/R cHL, regardless of SCT eligibility.	Bendamustine Hydrochloride	43-55	chordin like 1	Homo sapiens	109-112
34249005-0	2021	Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.	Bendamustine Hydrochloride	38-50	FMS-like tyrosine kinase 3	Mus musculus	80-84
34249005-5	2021	Here, we demonstrate that exposure to BEN increases Flt3 expression on both murine bone marrow-derived DCs (BMDCs) and human monocyte-derived DCs (moDCs).	Bendamustine Hydrochloride	38-41	FMS-like tyrosine kinase 3	Mus musculus	52-56
34249005-8	2021	BEN exposure and heightened Flt3 signaling are associated with a distinct regulatory phenotype, with increased PD-L1 expression and decreased ICOS-L expression.	Bendamustine Hydrochloride	0-3	CD274 antigen	Mus musculus	111-116
34249005-8	2021	BEN exposure and heightened Flt3 signaling are associated with a distinct regulatory phenotype, with increased PD-L1 expression and decreased ICOS-L expression.	Bendamustine Hydrochloride	0-3	icos ligand	Mus musculus	142-148
34249005-10	2021	These proliferative alloreactive T-cells expressed greater levels of PD-1 and underwent increased programmed cell death as the concentration of BEN exposure increased.	Bendamustine Hydrochloride	144-147	programmed cell death 1	Mus musculus	69-73
34249005-11	2021	Alloreactive CD4+ T-cell death may be attributable to pre-cDC1s and provides a potential mechanism by which BEN+TBI conditioning limits GvHD and yields T-cells tolerant to host antigen.	Bendamustine Hydrochloride	108-112	CD4 antigen	Mus musculus	13-16
35577753-6	2022	In the first case, a patient with CLL, complex karyotype, del 17p, and a mutation in TP53 experiences progression after ibrutinib, venetoclax, bendamustine, rituximab, and idelalisib.	Bendamustine Hydrochloride	143-155	tumor protein p53	Homo sapiens	85-89
35439335-4	2022	Bendamustine induced mitochondria-mediated apoptosis in concentration- and time-dependent manners in NKTCL cells, shown as down-regulation of Bcl-2 and activation of cleavage of caspases 3, 7, 9 and poly adenosinediphosphate-ribose polymerase (PARP).	Bendamustine Hydrochloride	0-12	B cell leukemia/lymphoma 2	Mus musculus	142-147
35439335-4	2022	Bendamustine induced mitochondria-mediated apoptosis in concentration- and time-dependent manners in NKTCL cells, shown as down-regulation of Bcl-2 and activation of cleavage of caspases 3, 7, 9 and poly adenosinediphosphate-ribose polymerase (PARP).	Bendamustine Hydrochloride	0-12	poly (ADP-ribose) polymerase family, member 1	Mus musculus	199-242
35439335-4	2022	Bendamustine induced mitochondria-mediated apoptosis in concentration- and time-dependent manners in NKTCL cells, shown as down-regulation of Bcl-2 and activation of cleavage of caspases 3, 7, 9 and poly adenosinediphosphate-ribose polymerase (PARP).	Bendamustine Hydrochloride	0-12	poly (ADP-ribose) polymerase family, member 1	Mus musculus	244-248
35439335-5	2022	Bendamustine arrested NKTCL cells in G2/M phase, with downregulation of expression of cyclin B1 and upregulation of expression of p-cdc2, p-cdc25c and p-P53.	Bendamustine Hydrochloride	0-12	cyclin B1	Mus musculus	86-95
35439335-5	2022	Bendamustine arrested NKTCL cells in G2/M phase, with downregulation of expression of cyclin B1 and upregulation of expression of p-cdc2, p-cdc25c and p-P53.	Bendamustine Hydrochloride	0-12	cyclin-dependent kinase 1	Mus musculus	132-136
35439335-5	2022	Bendamustine arrested NKTCL cells in G2/M phase, with downregulation of expression of cyclin B1 and upregulation of expression of p-cdc2, p-cdc25c and p-P53.	Bendamustine Hydrochloride	0-12	cell division cycle 25C	Mus musculus	140-146
35439335-5	2022	Bendamustine arrested NKTCL cells in G2/M phase, with downregulation of expression of cyclin B1 and upregulation of expression of p-cdc2, p-cdc25c and p-P53.	Bendamustine Hydrochloride	0-12	transformation related protein 53, pseudogene	Mus musculus	153-156
35439335-6	2022	Furthermore, we confirmed that bendamustine activated DNA damage response (DDR) directly or through Ataxia Telangiectasia Mutated Protein (ATM)/Chk2 and ATR/Chk1 pathway and increased the intracellular reactive oxygen species (ROS) level in NKTCL cells, which caused G2/M phase arrest and apoptosis.	Bendamustine Hydrochloride	31-43	ataxia telangiectasia mutated	Mus musculus	100-137
35439335-6	2022	Furthermore, we confirmed that bendamustine activated DNA damage response (DDR) directly or through Ataxia Telangiectasia Mutated Protein (ATM)/Chk2 and ATR/Chk1 pathway and increased the intracellular reactive oxygen species (ROS) level in NKTCL cells, which caused G2/M phase arrest and apoptosis.	Bendamustine Hydrochloride	31-43	ataxia telangiectasia mutated	Mus musculus	139-142
35439335-6	2022	Furthermore, we confirmed that bendamustine activated DNA damage response (DDR) directly or through Ataxia Telangiectasia Mutated Protein (ATM)/Chk2 and ATR/Chk1 pathway and increased the intracellular reactive oxygen species (ROS) level in NKTCL cells, which caused G2/M phase arrest and apoptosis.	Bendamustine Hydrochloride	31-43	checkpoint kinase 2	Mus musculus	144-148
35439335-6	2022	Furthermore, we confirmed that bendamustine activated DNA damage response (DDR) directly or through Ataxia Telangiectasia Mutated Protein (ATM)/Chk2 and ATR/Chk1 pathway and increased the intracellular reactive oxygen species (ROS) level in NKTCL cells, which caused G2/M phase arrest and apoptosis.	Bendamustine Hydrochloride	31-43	ataxia telangiectasia and Rad3 related	Mus musculus	153-156
35439335-6	2022	Furthermore, we confirmed that bendamustine activated DNA damage response (DDR) directly or through Ataxia Telangiectasia Mutated Protein (ATM)/Chk2 and ATR/Chk1 pathway and increased the intracellular reactive oxygen species (ROS) level in NKTCL cells, which caused G2/M phase arrest and apoptosis.	Bendamustine Hydrochloride	31-43	checkpoint kinase 1	Mus musculus	157-161
35439335-7	2022	Bendamustine also inhibited phosphorylation of transcriptional factor STAT3, contributing to cell apoptosis and proliferation inhibition.	Bendamustine Hydrochloride	0-12	signal transducer and activator of transcription 3	Mus musculus	70-75
35439335-10	2022	These findings demonstrate that bendamustine activates DDR pathway, induces the accumulation of intracellularROS level as well as inhibition of STAT3, leading to cell apoptosis and G2/M cell cycle arrest in NKTCL cells, which indicates that bendamustine dramatically suppressed NKTCL both in vitro and in vivo and provides a potential therapeutic strategy in the treatment of NK/T lymphoma.	Bendamustine Hydrochloride	32-44	signal transducer and activator of transcription 3	Mus musculus	144-149
35220927-0	2022	BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis.	Bendamustine Hydrochloride	4-16	chromosome 12 open reading frame 73	Homo sapiens	0-2
34987165-7	2022	Bendamustine was a better chemotherapy backbone than CHOP either with maintenance (R-Benda-R vs R-CHOP-R, HR = 0.62; G-Benda-G vs G-CHOP-G, HR = 0.55) or without maintenance therapy (R-Benda vs R-CHOP, HR = 0.68).	Bendamustine Hydrochloride	0-12	DNA damage inducible transcript 3	Homo sapiens	98-102
34987165-7	2022	Bendamustine was a better chemotherapy backbone than CHOP either with maintenance (R-Benda-R vs R-CHOP-R, HR = 0.62; G-Benda-G vs G-CHOP-G, HR = 0.55) or without maintenance therapy (R-Benda vs R-CHOP, HR = 0.68).	Bendamustine Hydrochloride	0-12	DNA damage inducible transcript 3	Homo sapiens	196-200